Abstract

PAPA, Mercedes Patricia. Uso del metilfenidato en pacientes con cáncer avanzado. Rev. Méd. Urug. [online]. 2013, vol.29, n.1, pp.58-63. ISSN 1688-0390.

Summary Introduction: Cancer, both the disease and its treatment are associated with a series of physical and psychosocial symptoms such as fatigue, depression, drowsiness and hypoactive delirium that need to be identified and treated in order to optimize the patients' quality of life. Methylphenidate, a psychostimulant drug used for the attention deficit disorder, is used within the context of palliative medicine to control these symptoms in patients suffering from advanced cancer. Objectives: The present articles aims to explore the evidence that justifies the use of this drug in the symptomatic handling of oncological patients, as well as its efficacy and safety in this population. Method: We conducted a search in the Medline, Pubmed y Embase databases, both in English and in Spanish, from 1990 until today. Conclusions: Methylphenidate is the most widely used psychostimulant in palliative medicine. As it increases the level of brain alert it results in a potential benefit for the handling of symptoms in patients with advanced cancer, such as the cancer associated fatigue, sedation associated to the use of opioids, depression and hypoactive delirium.

Keywords : METHYLPHENIDATE [therapeutic use]; DEPRESSION; DELIRIUM; FATIGUE; NEOPLASMS PALLIATIVE CARE.

        · abstract in Spanish | Portuguese     · text in Spanish     · Spanish ( pdf )